Keywords: sugammadex, gets, not-approvable, fda, letter, s-p, working
Sugammadex gets "not-approvable" FDA letter; S-P working to resolve issues
Article | 11 August 2008
Shares in Schering-Plough dropped 3.2% to $20.41 on August 1, after the US Food and Drug Administration sent the drug major a "not-approvable" ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
